Skip to main content
Top
Published in: Diabetologia 8/2012

01-08-2012 | Commentary

The rise and fall of HbA1c as a risk marker for diabetes complications

Author: E. S. Kilpatrick

Published in: Diabetologia | Issue 8/2012

Login to get access

Abstract

It is still unclear whether short-term, within-day, variability in glycaemic control is contributory to the development of diabetes micro- or macrovascular complications. However, consistent and compelling data are emerging that longer term fluctuations in glucose, as evidenced by increases in HbA1c variability, do indeed add to the mean HbA1c value in predicting the risk of microvascular disease. Until now, studies have found this to be the case mainly in type 1 diabetes, but in this issue of Diabetologia (DOI: 10.​1007/​s00125-012-2572-7) an analysis of the Tsukuba Kawai Diabetes Registry in Japan has found that HbA1c variability also predicts the risk of nephropathy in type 2 diabetic patients. These observations raise the possibility that reducing rises and falls in HbA1c may help avoid hyperglycaemia-related vascular disease without running the same risk of hypoglycaemia that a strategy focusing purely on lower HbA1c might incur.
Literature
1.
go back to reference Sugawara A, Kawai K, Motohashi S (2012) HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia. doi:10.1007/s00125-012-2572-7 Sugawara A, Kawai K, Motohashi S (2012) HbA1c variability and the development of microalbuminuria in type 2 diabetes: Tsukuba Kawai Diabetes Registry 2. Diabetologia. doi:10.​1007/​s00125-012-2572-7
2.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 29:1486–1490PubMedCrossRef
3.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2009) Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes. Diabetes Care 32:1901PubMedCrossRef
4.
go back to reference Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JBL, DeVries JH (2009) Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229–2232PubMedCrossRef Siegelaar SE, Kilpatrick ES, Rigby AS, Atkin SL, Hoekstra JBL, DeVries JH (2009) Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT. Diabetologia 52:2229–2232PubMedCrossRef
5.
go back to reference Home PD (2005) Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989–998PubMedCrossRef Home PD (2005) Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989–998PubMedCrossRef
6.
go back to reference Raz I, Wilson PWF, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381–386PubMedCrossRef Raz I, Wilson PWF, Strojek K et al (2009) Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care 32:381–386PubMedCrossRef
7.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 31:2198–2202PubMedCrossRef Kilpatrick ES, Rigby AS, Atkin SL (2008) A1C variability and the risk of microvascular complications in type 1 diabetes. Diabetes Care 31:2198–2202PubMedCrossRef
8.
go back to reference Wadèn J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, Finnish Diabetic Nephropathy Study Group (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef Wadèn J, Forsblom C, Thorn LM, Gordin D, Saraheimo M, Groop PH, Finnish Diabetic Nephropathy Study Group (2009) A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 58:2649–2655PubMedCrossRef
9.
go back to reference Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011–1013PubMedCrossRef Marcovecchio ML, Dalton RN, Chiarelli F, Dunger DB (2011) A1C variability as an independent risk factor for microalbuminuria in young people with type 1 diabetes. Diabetes Care 34:1011–1013PubMedCrossRef
10.
go back to reference Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569CrossRef Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group (2002) Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287:2563–2569CrossRef
11.
go back to reference Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef Nathan DM, Cleary PA, Backlund JY et al (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653PubMedCrossRef
12.
go back to reference Ihnat M, Thorpe J, Ceriello A (2007) Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med 24:582–586PubMedCrossRef Ihnat M, Thorpe J, Ceriello A (2007) Hypothesis: the ‘metabolic memory’, the new challenge of diabetes. Diabet Med 24:582–586PubMedCrossRef
13.
go back to reference The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
14.
go back to reference Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef Stratton IM, Adler AI, Neil HA et al (2000) Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405–412PubMedCrossRef
15.
go back to reference The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116:874–886 The Diabetes Control and Complications Trial Research Group (1998) Early worsening of diabetic retinopathy in the diabetes control and complications trial. Arch Ophthalmol 116:874–886
16.
go back to reference Bolen SD, Bricker E, Samuels TA et al (2009) Factors associated with intensification of oral diabetes medications in primary care provider–patient dyads: a cohort study. Diabetes Care 32:25–31PubMedCrossRef Bolen SD, Bricker E, Samuels TA et al (2009) Factors associated with intensification of oral diabetes medications in primary care provider–patient dyads: a cohort study. Diabetes Care 32:25–31PubMedCrossRef
Metadata
Title
The rise and fall of HbA1c as a risk marker for diabetes complications
Author
E. S. Kilpatrick
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 8/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-012-2610-5

Other articles of this Issue 8/2012

Diabetologia 8/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine